Sign in

Trial result ·

Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This trial tested paxalisib, a drug that can reach the brain. It was given with trastuzumab. People had HER2-positive breast cancer that had spread to the brain. Their brain tumors were active or growing. People with cancer in the brain lining were left out. The trial first set a dose, then gave it to more people. The team also tested tumor DNA in blood and spinal fluid.

What they found

The median age was 44 years. People had a median of 5 earlier lines of treatment. The chosen dose was paxalisib 30 mg daily plus trastuzumab. Among 12 people at this dose, no brain tumors shrank enough to count. So the study was closed, as it was not working. Median survival was 16.5 months. Side effects were in line with drugs that block PI3K and mTOR. Spinal fluid had a larger tumor share of free DNA than blood. Changes in this share tracked the amount of tumor in the brain.

What it means for patients

The authors say the drug pair could be given to these people. But it did not reach its main goal of shrinking brain tumors. They say it showed very little effect in this heavily treated group. Tests on spinal fluid may show tumor genes and response better than blood. The authors say this supports using spinal fluid in future research.

Why it is not certain yet

Only 12 people got the chosen dose. The abstract describes no comparison group. All people had been heavily treated before. People with cancer in the brain lining were not included. The spinal fluid and blood tests were exploratory, so they need more study.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses.

PubMed · PMID 42895898

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Brain metastases publications